Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMEL1 | Q495T6 | 11/20 | 0.54 |
| ▸ | ACE | P12821 | 4/20 | 0.43 |
| ▸ | EMG1 | Q92979 | 2/20 | 0.43 |
| ▸ | MME | P08473 | 7/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10197740 | 0.91 | MMEL1 (0.48) | MMEL1MME | |
| SCHEMBL14959422 | 0.90 | MMEL1 (0.59) | MMEL1ACEMME | |
| SCHEMBL12975389 | 0.87 | MMEL1 (0.53) | MMEL1ACEEMG1MMEMAPT | |
| SCHEMBL2875342 | 0.85 | MMEL1 (0.60) | MMEL1ACEEMG1MMEMAPT | |
| SCHEMBL2875347 | 0.85 | MMEL1 (0.60) | MMEL1ACEEMG1MMEMAPT | |
| SCHEMBL14959424 | 0.81 | MMEL1 (0.60) | MMEL1MME | |
| SCHEMBL2872628 | 0.79 | MMEL1 (0.67) | MMEL1ACEMMEMAPT | |
| SCHEMBL2872629 | 0.79 | MMEL1 (0.67) | MMEL1ACEMMEMAPT | |
| SCHEMBL12975580 | 0.78 | MMEL1 (0.58) | MMEL1ACEEMG1MME | |
| SCHEMBL2876313 | 0.78 | MMEL1 (0.57) | MMEL1ACEMMEMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140296240-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | COPPOLA GARY MARK (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140296240-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | COPPOLA GARY MARK (US) | 2014-10-02 | — | — | US | disclosed |
| US-8822534-B2 | Substituted aminopropionic derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| US-8822534-B2 | Substituted aminopropionic derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| EP-2435409-B1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2014-08-13 | — | — | EP | disclosed |
| EP-2594556-A1 | Substituted aminopropionic derivatives as neprilysin inhibitors | Novartis AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| EP-2594557-A1 | Substituted aminopropionic derivatives as neprilysin inhibitors | Novartis AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| US-20130096127-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2013-04-18 | — | — | US | disclosed |
| US-20130096127-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2013-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296240-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | MME, AGTR1, REN | MMEL1 299/4885ACE 4/4885EMG1 3819/4885 |
| US-20130096127-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | MME, AGTR1, REN | MMEL1 299/4885ACE 4/4885EMG1 3819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.